Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
11. |
ECCT/25/11/06 | MK-8527-011 Study A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. Dr Maricianah Onono Site(s) in Kenya 1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county) 2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) 3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county) |
View |
12. |
ECCT/25/08/05 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Dr. Isaac Tsikhutsu Site(s) in Kenya 1. KEMRI WALTER REED KERICHO (Kericho county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrudes Childrens Hospital (Nairobi City county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 7. KEMRI Kondele Children\'s Hospital (Kisumu county) |
View |
13. |
ECCT/25/08/04 | MK-8527-010 PrEP A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) |
View |
14. |
ECCT/25/08/06 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Irene Wambui Inwani Site(s) in Kenya 1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county) 2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county) 3. Kargeno Research & Policy Hub (Kisumu county) 4. KEMRI-CCR-PHRD, Thika site (Kiambu county) |
View |
15. |
ECCT/25/11/04 | Bifin02 and LGG® A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research (Uasin Gishu county) 2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county) |
View |